New mRNA vaccine trial targets Virus-Linked cancers
NCT ID NCT07349836
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests an mRNA immunotherapy for people with tumors linked to the Epstein-Barr virus, such as nasopharyngeal cancer, gastric cancer, and lymphoma. The treatment aims to help the immune system recognize and attack cancer cells. Researchers will check safety and whether the drug shrinks tumors or slows disease growth, both alone and combined with standard immune-boosting drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV DISEASE AFTER HSCT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Could muscle loss predict blood cancer outcomes?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?